Drug Trial Radar · NCT07868172
GST101 in Participants With RAS-Mutant Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
172
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Genuine Seed Therapeutics (Zhuhai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase I/II trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral GST101 in adult participants with RAS-mutant advanced solid tumors. Phase I consists of dose escalation and dose-expansion parts. Dose escalation uses accelerated titration design combined with 3+3 design to determine maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Safety, dose-limiting-toxicity (DLT), PK and preliminary efficacy will be assessed. Phase II (indication-exploration) enrolls participants in four tumor-specific cohorts including RAS-mutant NSCLC, colorectal cancer, pancreatic ductal adenocarcinoma and other advanced solid tumors refractory to standard-of-care therapies. Participants receive GST101 orally once-daily in 21-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or loss of clinical benefit. Tumor assessments follow RECIST 1.1. Safety, PK, QTc and exploratory biomarker analyses will be performed.
Conditions
- RAS-mutant Advanced Solid Tumors
Interventions
GST101Drug
5 mg oral tablet, administered once daily. Participants are assigned to different dose-level cohorts (10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg). Fasting requirement: 1-hour fast prior to dosing and 2-hour fast after dosing. Each treatment cycle is 21-days. Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or no further clinical benefit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEsTime frame: Up to 36 months
- Maximum Tolerated Dose (MTD)Time frame: Up to 12 months
- Recommended Phase 2 Dose (RP2D)Time frame: Up to 12 months
- Objective Response Rate (ORR)Time frame: Up to 36 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Not yet recruiting
Shandong Cancer Hospital and Institute
Jinan, Shandong, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.